Eurobio Scientific SA
PAR:ALERS
ALERS's latest stock split occurred on Sep 1, 2017
The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.
Before the split, ALERS traded at 0.29 per share. Afterward, the share price was about 5.89.
The adjusted shares began trading on Sep 1, 2017. This was ALERS's 2nd stock split, following the previous one in Jan 30, 2017.
YLLWF
CMB
RNT
Eurobio Scientific SA
Glance View
Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
You don't have any saved screeners yet